Cormedix Inc is a biopharmaceutical company focused on developing innovative therapies aimed at improving the lives of patients with serious medical conditions. The company primarily concentrates on treatments for infections related to catheter use and other healthcare-associated infections. Cormedix is dedicated to advancing its proprietary product candidates through clinical trials and regulatory pathways, with an emphasis on addressing unmet medical needs in the fields of nephrology and infectious diseases. Through its research and development efforts, Cormedix aims to provide effective and safe therapeutic solutions that enhance patient outcomes. Read More
CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
Chairman and Chi
CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.
CorMedix (CRMD) exemplifies a high-growth stock with explosive sales, strong earnings momentum, and robust profitability, fitting a proven investment framework.
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.
